Haemonetics Corporation stocks have been trading up by 15.96 percent after strong earnings and upbeat guidance bolstered investor confidence.
Key Takeaways
- Citigroup upgraded Haemonetics from Neutral to Buy and hiked its price target to $123, well above the prior Street average near $108.40.
- Shares of HAE climbed about 2.4% after the upgrade, as traders reacted to the higher $123 target versus the previous $92 level.
- Citi pointed to earnings upside from a new non-exclusive CSL supply agreement, estimating every 10% share recapture adds $0.13 to EPS.
- The Vivasure deal is progressing, triggering a $6.1M milestone to Orchestra BioMed and setting up as much as $10M in future earnouts.
- Haemonetics scheduled its Q2 FY2027 earnings release and call for 2026/11/05, marking the next key catalyst for HAE traders.
Live Update At 12:32:31 EDT: On Thursday, October 08, 2026 Haemonetics Corporation stock [NYSE: HAE] is trending up by 15.96%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
HAE has been grinding higher for weeks, then exploded on the Citigroup upgrade. From late September around $105–$109, Haemonetics pushed to a closing high near $117.94 on 2026/10/08, with an intraday move as high as $121. That is a clean breakout above the prior tight range and gives HAE traders a fresh momentum trend to track.
Under the hood, Haemonetics is a classic high-margin medtech story. Gross margin sits near 59%, which is strong, but the profit margin around 7% and an EBIT margin of 3.5% show there is still a lot of spending and leverage in the model. Revenue over the last year is about $1.33B, with mid‑single‑digit growth in recent periods.
More Breaking News
The latest quarter (ended 2026/06/27) showed $339.38M in revenue and $0.72 in diluted EPS. Operating income was $57.46M, and free cash flow ran about $44.42M. HAE carries meaningful debt — roughly $1.17B of long‑term borrowings — but has solid coverage, with interest expense of about $9.88M and a current ratio of 3.1. For traders, that means Haemonetics has room to execute, but premium valuation (about 50x earnings and 3.5x sales) demands continued performance.
Why Traders Are Watching HAE Now
The Citigroup call is the spark bringing HAE onto more trading screens. The firm upgraded Haemonetics from Neutral to Buy and raised its price target to $123, topping the prior analyst mean target near $108.40. When a big bank steps up like that, especially above the Street average, short‑term traders pay attention. It signals fresh institutional conviction.
The market reaction backed that up. After the upgrade and target bump from $92 to $123, HAE rallied about 2.4%, with the stock trading around $108 at the time and then pressing into the high‑teens. Volume was actually below average, which tells nimble traders something important: the move is driven more by re‑rating than by a full‑on momentum stampede. That leaves room for latecomers to still find edges, especially on intraday pullbacks toward prior resistance levels.
Citi’s reasoning matters just as much as the headline. The firm is leaning on a new non‑exclusive supply agreement with CSL, expecting earnings upside as Haemonetics recaptures share. Each 10% share recapture is pegged at about $0.13 in EPS, which is real leverage for a company currently printing around $0.70 per quarter. For HAE traders, that frames a simple story: if CSL volumes ramp the way Citi models, the current 50x P/E begins to look more reasonable.
On top of that, Haemonetics’ acquisition of Vivasure continues to move forward. A $6.1M milestone payment to Orchestra BioMed was triggered, completing $11M in consideration and setting up as much as $10M in future earnouts tied to Vivasure revenues. Progress on the PerQseal Elite vessel closure system is effectively being confirmed with cash. That adds a second growth leg to the HAE narrative beyond CSL, but it also brings ongoing obligations that conservative HAE traders will track.
Finally, Haemonetics put a date on the calendar: Q2 FY2027 results drop on 2026/11/05, with a webcast and replay. For short‑term players, that is the next hard catalyst where the CSL thesis and Vivasure integration start to show up — or not — in the numbers.
Conclusion
Right now HAE sits at an interesting crossroads for active traders. The chart shows a clear breakout from a month‑long consolidation around $105–$109 into the high‑teens and low‑$120s on the Citigroup upgrade. The fundamentals back the move: high gross margins, solid cash generation, and two tangible growth drivers in the CSL supply deal and the Vivasure platform.
At the same time, Haemonetics is not cheap. A P/E near 50 and price‑to‑sales around 3.5 mean traders are paying up for that growth. The balance sheet carries over $1.16B of long‑term debt, though interest coverage above 20x and a strong current ratio keep the risk manageable for now. The key question for HAE from here is simple: does upcoming execution fill in the earnings that Citi is now baking into its $123 target?
For traders in the Tim Sykes community, this is exactly the kind of setup to study: a catalyst‑driven breakout, clear levels on the chart, and a defined date — 2026/11/05 — where the story is tested. As Tim likes to remind traders, “react, don’t predict — let the price action confirm the story before you size up.” That focus on discipline over prediction lines up with another core lesson: as millionaire penny stock trader and teacher Tim Sykes says, “Consistency is key in trading; don’t let emotions dictate your trades.”. For HAE, that means watching how the stock behaves on pullbacks toward prior resistance and how it responds to the next earnings call. This article is for educational and research purposes only and is not investment advice.
This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.
Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:
- Penny Stocks Trading Guide
- Best Penny Stocks Under $1 to Buy Today
- Top 8 Penny Stocks to Watch on Robinhood
Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:
Leave a reply